Skip to main content
Premium Trial:

Request an Annual Quote

Tepnel Gets CE Mark for DNA-Based Cholesterol Test

NEW YORK (GenomeWeb News) – Tepnel Life Sciences said today that its DNA-based test for the early detection of familial hypercholesterolemia has received the CE Mark and has been commercially launched in Europe.
 
Manchester, England-based Tepnel said that the Elucigene FH20 kit can rapidly determine the 20 genetic mutations responsible for the disease that are most commonly found in a UK-based population.
 
The firm said the test has been cleared and launched in advance of a guidance document from the National Institute for Clinical Excellence in England that is expected to recommend that FH patients be offered a DNA test with subsequent screening to be performed if the mutations are identified in a patient.
 
Tepnel said that in a pilot study the test identified a 52 percent mutation detection rate in a sample of 110 FH heterozygous patients. “For effective treatment, early identification of persons with FH is essential and FH20 offers the [National Health Service] the right tool at the right time to implement the new clinical practice guidelines,” said Tepnel CEO Ben Matzilevich in a statement.
 
The test has not been cleared for clinical diagnostic use in the US, Tepnel noted.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.